OncoMatch/Clinical Trials/NCT04561492

Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma

Is NCT04561492 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies [68Ga]Ga-PentixaFor for multiple myeloma.

Phase 2RecruitingNantes University HospitalNCT04561492Data as of May 2026

Treatment: [68Ga]Ga-PentixaFor — The aim of our study is to confirm the relevance of PET using \[68Ga\]Ga -PentixaFor ligand, in comparison with FDG, for initial staging and therapeutic evaluation of symptomatic multiple myeloma patients in first line treatment or in relapse. The prognostic value of positive CXCR4 expression will also be assessed and \[68Ga\]Ga -PentixaFor/FDG discordances explored.

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Kidney function

eGFR < 50 ml/min by MDRD or CKDEPI [excluded]

eGFR < 50 ml/min by MDRD or CKDEPI

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify